Literature DB >> 9124843

Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate.

C E Thorburn1, S J Molesworth, R Sutherland, S Rittenhouse.   

Abstract

The postantibiotic effect (PAE) of amoxicillin-clavulanate was studied for strains of Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, Klebsiella pneumoniae, and Escherichia coli. A PAE of approximately 2 h was seen for beta-lactamase-positive and -negative strains of S. aureus following 2 h of exposure to twice the MIC and did not increase at 16 times the MIC. The PAE observed with H. influenzae was clearly related to the growth rate of the organism. A PAE of 0.8 h was found for amoxicillin (four times the MIC) against a beta-lactamase-negative strain of H. influenzae (generation time, 26.3 min) and a PAE of 1.74 h was found for amoxicillin-clavulanate (twice the MIC) against a beta-lactamase-positive strain (generation time, 32.2 min). When the beta-lactamase-positive strain was growing more slowly (generation time, 120 min), the PAE of amoxicillin-clavulanate increased to > 3.32 h. The PAE of amoxicillin-clavulanate at 2/1 micrograms/ml on a beta-lactamase-producing strain of M. catarrhalis was > 2.9 h, and, as expected, the PAEs of twice the MIC on K. pneumoniae and E. coli were generally short (< 1 h). The post-beta-lactamase inhibitor effect (PLIE), determined after removal of only clavulanate, was also examined for beta-lactamase-positive strains. This was more prolonged (approximately 3 to 4 h) than the corresponding PAE for S. aureus, H. influenzae, and M. catarrhalis. The PLIE was related to the amount of beta-lactamase produced and required the presence of amoxicillin in the initial exposure period. These data may have implications for reducing the dosage of amoxicillin-clavulanate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124843      PMCID: PMC163624     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Continuous versus discontinuous antibiotic therapy: the role of the post-antibiotic effect and other factors.

Authors:  G K Daikos
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

Review 2.  The postantibiotic effect: a review of in vitro and in vivo data.

Authors:  G G Zhanel; D J Hoban; G K Harding
Journal:  DICP       Date:  1991-02

3.  THE SLOW RECOVERY OF BACTERIA FROM THE TOXIC EFFECTS OF PENICILLIN.

Authors:  H Eagle; A D Musselman
Journal:  J Bacteriol       Date:  1949-10       Impact factor: 3.490

4.  Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man.

Authors:  F Fraschini; F Scaglione; M Falchi; S Dugnani; M Mezzetti; F Cicchetti; G Alfano; G P Pintucci
Journal:  J Chemother       Date:  1990-06       Impact factor: 1.714

5.  Growth kinetics of respiratory pathogens after short exposures to ampicillin and erythromycin in vitro.

Authors:  A U Gerber; W A Craig
Journal:  J Antimicrob Chemother       Date:  1981-11       Impact factor: 5.790

6.  Pharmacodynamic effects of subinhibitory concentrations of beta-lactam antibiotics in vitro.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

7.  The recovery period following exposure of bacteria to penicillins.

Authors:  D A Wilson; G N Rolinson
Journal:  Chemotherapy       Date:  1979       Impact factor: 2.544

8.  Comparison of two methods for determining in vitro postantibiotic effects of three antibiotics on Escherichia coli.

Authors:  D L Rescott; D E Nix; P Holden; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

9.  Postantibiotic effect of imipenem on Pseudomonas aeruginosa.

Authors:  C I Bustamante; G L Drusano; B A Tatem; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

  9 in total
  6 in total

Review 1.  New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.

Authors:  Amparo Sánchez Navarro
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Selection of retapamulin, a novel pleuromutilin for topical use.

Authors:  Stephen Rittenhouse; Sanjoy Biswas; John Broskey; Lynn McCloskey; Terrance Moore; Sandra Vasey; Joshua West; Magdalena Zalacain; Rimma Zonis; David Payne
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

3.  Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.

Authors:  Helio S Sader; Paul R Rhomberg; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

Review 4.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Ex vivo pharmacodynamics of amoxicillin-clavulanate against beta-lactamase-producing Escherichia coli in a yucatan miniature pig model that mimics human pharmacokinetics.

Authors:  Stéphane Bronner; Valérie Murbach; Jean-Daniel Peter; Dominique Levêque; Hassan Elkhaïli; Yves Salmon; Nathalie Dhoyen; Henri Monteil; Gary Woodnutt; François Jehl
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii.

Authors:  Alejandro Beceiro; Rafael López-Rojas; Juan Domínguez-Herrera; Fernando Docobo-Pérez; Germán Bou; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.